Havas has made an investment in and partnership with Ostro, the AI-powered platform designed to improve engagements between consumers, healthcare providers and brands in the pharmaceutical, biotech, medical devices and related sectors. Investment details were not disclosed.  

Six-year-old Ostro rebranded from RxDefine in 2022 after receiving an additional $45 million in funding from investors, bringing its total funding at the time to $55 million.   

With the deal the Ostro platform will initially support Havas Health Network clients, with plans to expand across Havas Creative and Media Networks—providing content workflows, omnichannel activations, and enhanced media precision, according to the company.  

Havas CEO Yannick Bollore said the pact was representative of the Group’s previously stated commitment to spend roughly $450 million over the next four years to further develop its data, technology and AI capabilities.   “This partnership aims to unlock new levels of insight, modular content delivery, and optimized omnichannel performance through Ostro’s cutting-edge solutions” and Havas’ brand expertise, he added.